Nama's AI scorecard currently rates AdaptHealth Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AHCO's P/E ratio?

AdaptHealth trades at a trailing price-to-earnings ratio of 33.3.

When does AHCO report earnings?

AdaptHealth's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.06.

What is the AHCO price target?

The median analyst price target from 7 analysts is $9.00, with a range of $7.00 – $10.00.

Is AHCO Shariah compliant?

Nama's AAOIFI-style screen reads AdaptHealth as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

AdaptHealth (AHCO)

Healthcare · Medical Devices · NASDAQ

AdaptHealth (AHCO) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.00B, a trailing price-to-earnings ratio of 33.3 and a free-cash-flow yield of 22.1%. Over the most recent reported fiscal year, revenue declined 0.5% and free cash flow per share fell 6.7%. Nama's AI scorecard rates it Sell, 3.1 out of 10.

AI scorecard

Sell · 3.1/10

Negative, at the mild end of Sell. As of Nov 6, 2026.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-73.3%

How far the last close sits under the highest price of the past five years.

Market cap	$1.00B
Trailing P/E	33.3
Price / book	0.7
Price / sales	0.3
FCF yield	22.1%
Dividend yield	—
Gross margin	17.8%
Operating margin	3.3%
Net margin	-7.0%
Revenue growth (YoY)	-0.5%
Revenue growth (3-yr annual)	+3.0%
EPS growth (YoY)	-41.6%
FCF/share growth (YoY)	-6.7%
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

AHCO earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$0.06). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.07	-$0.06	+216.7%	$568.33M
Q2 2026	Aug 4, 2026	-$0.07	$0.17	-141.2%	$567.53M
Q1 2026	May 5, 2026	-$0.05	$0.01	-600.0%	$614.32M
Q4 2025	Feb 24, 2026	$0.27	$0.34	-20.6%	$1.47B

AHCO analyst price target

Median target $9.00 from 7 analysts, ranging $7.00 – $10.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live AHCO data on Nama Insights →

AHCO FAQ

Is AHCO a buy?: Nama's AI scorecard currently rates AdaptHealth Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AHCO's P/E ratio?: AdaptHealth trades at a trailing price-to-earnings ratio of 33.3.
When does AHCO report earnings?: AdaptHealth's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.06.
What is the AHCO price target?: The median analyst price target from 7 analysts is $9.00, with a range of $7.00 – $10.00.
Is AHCO Shariah compliant?: Nama's AAOIFI-style screen reads AdaptHealth as Not Shariah Compliant. At least one of the three ratios or the industry test failed.